Atlas Trials

Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Clinical trial NCT01606982 · APPROVED_FOR_MARKETING

Trial details

NCT number
NCT01606982
Sponsor
Astellas Pharma Global Development, Inc.
Status
APPROVED_FOR_MARKETING
Study type
EXPANDED_ACCESS
Metastatic Castration-Resistant Prostate Cancer

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.